ADA-SCID Gene Therapy Endorsed By European Medicines Agency For Marketing Authorization-Reference-Cited by-同舟云学术

ADA-SCID Gene Therapy Endorsed By European Medicines Agency For Marketing Authorization

Published:2016-06 Issue:6 Volume:24 Page:1013-1014
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Ylä-Herttuala Seppo

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference9 articles.

1. European Medicines Agency 2016 Summary of opinion. Strimvelis. Autologous CD34+-enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/003854/WC500203918.pdf 1 April 2016

2. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency;Hershfield,2001

3. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years;Blaese;Science,1995

4. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients;Bordignon;Science,1995

5. Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency;Onodera;Blood,1998

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Production and Use of Gesicles for Nucleic Acid Delivery;Molecular Biotechnology;2021-10-01

2. The Landscape of Early Clinical Gene Therapies outside of Oncology;Molecular Therapy;2019-10

3. Severe Combined Immunodeficiency: A Review for Neonatal Clinicians;NeoReviews;2019-06-01

4. Gene therapy clinical trials worldwide to 2017: An update;The Journal of Gene Medicine;2018-04-19

5. Lentiviral Vector Promoter is Decisive for Aberrant Transcript Formation;Human Gene Therapy;2017-10